Mount Sinai Dermatology

11/24/2025

Shannon Meledathu, visiting medical student and first author, contributed tremendously to research led by Dr. Patrick Brunner and our Mount Sinai Dermatology team using single cell RNA sequencing to analyze the biology of mogamulizumab associated drug rash 🔬✨. Through this multidisciplinary team's careful and diligent work, they profiled more than seventy nine thousand individual cells from MAR, untreated CTCL, and healthy skin, revealing a marked depletion of malignant CCR4 positive T cell clones in MAR together with a collapse of key immunosuppressive signaling pathways. The few residual malignant clones displayed reduced migratory and central memory programs and increased tumor suppressor expression, indicating a transcriptionally silenced state rather than active lymphoma proliferation 🧬.

📚 https://bit.ly/43vyIZ4

Polyclonal T cells in MAR showed reduced exhaustion signatures and increased cytotoxic mediators, including GZMA and ZNF683, creating an immune milieu more capable of lymphoma control 💥. Stromal and myeloid compartments also shifted, with decreased C1Q associated immunosuppressive programs and increased expression of the tumor suppressor CEBPD in endothelial cells, fibroblasts, and macrophages. These multilevel changes illustrate how mogamulizumab reshapes the skin microenvironment, supporting antitumor immunity.

This study provides a detailed molecular explanation for the observed association between MAR and improved clinical outcomes and reinforces the importance of distinguishing MAR from true CTCL progression. The work exemplifies the power of collaborative investigation and the impact of rigorous trainee scholarship in advancing precision Dermatology.

The Mount Sinai Hospital
Icahn School of Medicine at Mount Sinai

11/21/2025

Dr. Emma Guttman, and team recently published in the British Journal of Dermatology: “Tape strips in inflammatory skin disease: a noninvasive method for molecular insights and personalized care”.
Tape stripping offers a minimally invasive method that provides valuable molecular insights into various skin and systemic diseases. This tool has enabled researchers & clinicians to monitor disease activity and evaluate therapeutic response, especially in pediatric patients who cannot tolerate repetitive biopsies. Tape strips are also being used to advance biomarker research in food allergy, asthma and other systemic and autoimmune diseases.
By facilitating data collection across diverse patient populations, tape strips are an important technological advancement towards precision medicine. Details: https://bit.ly/BJD_TapeStrips_EGuttman

Icahn School of Medicine at Mount Sinai The Mount Sinai Hospital

11/20/2025

Congratulations! We are grateful for
Amelia Morales 🌟
for celebrating 15 years with Mount Sinai. 👏 🙌
We deeply appreciate her dedication & hard work. The positive impact she continues to make every single day is truly inspiring.
The Mount Sinai Hospital Icahn School of Medicine at Mount Sinai

11/19/2025

Atopic dermatitis (AD) continues to challenge both patients and physicians, especially in cases where monotherapy does not provide sufficient control. Dr. Saakshi Khattri and colleagues at the Icahn School of Medicine at Mount Sinai have published a retrospective review highlighting the potential of combining biologics with small-molecule agents in adults with moderate-to-severe AD. This novel approach leverages distinct mechanisms of action, pairing IL-4/IL-13 blockade with Janus kinase inhibition, to tackle different arms of the inflammatory cascade. In a cohort of twenty-two patients, an impressive eighty-six percent achieved EASI-90 and fifty percent reached complete clearance with EASI-100 while on dual therapy. Importantly, the majority of adverse events were mild and manageable, with no severe reactions reported. ✨💊🧴

📚 https://bit.ly/4gYzW4C

These findings underscore the promise of dual therapy for patients whose disease remains refractory to single agents. Beyond offering an effective option for hard-to-treat AD, combination regimens may serve as a temporary bridge during severe flares before tapering to monotherapy. While limited by retrospective design and small sample size, the study reinforces the safety and efficacy of this strategy and adds valuable real-world evidence to the growing body of literature. For clinicians, this work challenges the conventional reliance on sequential monotherapy and highlights the potential for precision treatment tailored to disease severity and patient needs. For patients, it represents renewed hope for clear skin and improved quality of life. 🌟🧬💡

Mount Sinai Dermatology remains at the forefront of innovation in AD management, driving progress toward personalized and effective care strategies that transform outcomes. 🌍💙

The Mount Sinai Hospital

11/17/2025

Congratulations! We are grateful to
Crizaldo Custodio 🌟
for celebrating 25 years (!) with Mount Sinai! 👏 🙌
We're truly inspired by his hard work & dedication and grateful for the positive impact he continues to make every single day.
The Mount Sinai Hospital Icahn School of Medicine at Mount Sinai

11/15/2025

“Seborrheic Dermatitis” explored by Dr. Benjamin Ungar
-frequently associated with rosacea
-negative impact on quality of life
-perceptions of SD by patients vs. providers and more was discussed.

11/15/2025

Oral Presentations from Selected Abstracts:
“APG777, a Novel, Half-Life Extended Anti-IL-13 Antibody, Demonstrates Safety and Efficacy in Moderate-to-Severe Atopic Dermatitis: 16 Week Results From the Phase 2 APEX Study” was presented by Dr. Emma Guttman on the final day of
Rapid relief of itch, safety profile consistent with other therapies targeting IL-13 or IL-4/IL-13 pathway, and more were explored.

11/15/2025

11/14/2025

“Novel developments in pathogenesis of alopecia areata (AA) and how does it relate to atopic dermatitis (AD)?“ explored by Dr. Emma Guttman.
-AA might present a similar model to AD where cytokines suppress formation of hair keratins
-Evidence is mounting that AA belongs to the allergic spectrum
-Need better treatments for long term use and more were discussed at

11/14/2025

“Sensing Inflammation in the Skin and Beyond” was discussed by Dr. Brian Kim.
-Chronic puritis of unknown origin
-the sensory paradigm of cytokines/JAK signaling
-the disruptive field of Neuroimmunology and more were explored.

11/14/2025

Oral Presentations from Selected Abstracts:
“Nemolizumab suppressed multiaxial inflammatory pathways and improved barrier protein signatures in skin and blood proteomic analysis of patients with moderate-to-severe AD” presented by Daniel Liu, medical student

11/14/2025

Oral Presentations from Selected Abstracts:
“Single-Cell Transcriptomic Analysis Reveals Multicellular Drivers of Infl ammation in
Moderate- to-Severe Alopecia Areata”
presented by Benjamin Hu, medical student